Funding to accelerate large scale U.S. expansion with multinational customers beginning this month, amid growing demand from food companies to stabilize their egg supply chains

The EVERY Company, a biotechnology leader pioneering precision fermentation for highly functional proteins, today announced that it has successfully closed on $55 million in Series D financing. The round was led by McWin Capital Partners, through the McWin Food Tech Fund, with participation from Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian, SOSV, and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028242849/en/

Pound cake made with EVERY® OvoPro™

Proceeds from the Series D will be used to expand manufacturing capacity, move to profitability, and further expand its reach across the $270B egg market – particularly in the high-volume bakery segment.

“This new injection of capital will allow us to make good on our promise of making products that are accessible to everyone – in every state, every city, and every grocery store,” said Arturo Elizondo, Co-Founder and CEO of EVERY. “This milestone fundraise is a powerful validation of our ambitions and we’re grateful for the trust of our incredible investors.”

Mass Market Adoption and Commercial Expansion

This announcement underlines the strength and market viability of EVERY’s innovative approach to functional proteins, with its ingredients successfully commercialized across online platforms, retail markets, and foodservice channels as early indicators of market demand. Building on this momentum, EVERY is now strategically focused on scaling for mass-market adoption. Starting this month, EVERY’s proteins will be featured in products launching in Walmart, the world’s biggest retailer, and available on shelves nationwide.

“EVERY has crossed the line from promise to proof,” said Martin Davalos, Partner & Head of Food Tech at McWin Capital Partners. “They’re not talking about proof-of-concept pilots here - they’re selling metric tons of product at scale to some of the biggest food companies on the planet. EVERY is exactly the type of platform that will define the next decade of food production.”

Solving Traditional Supply Chain and Cost Instability

With egg prices swinging due to avian flu, supply issues, and higher feed costs, food makers are looking for more reliable ingredients. EVERY’s fermentation tech provides a stable, cage-free-compliant source of egg protein that performs as well as — or better than — conventional eggs.

Despite challenges across the alt-protein space, Elizondo says the core reason for diversifying protein sources hasn’t changed. “If the last two years have taught us anything, it’s that our current food system remains incredibly fragile. One outbreak can wipe out hundreds of millions of hens. For food companies small and large, that kind of risk just isn't tenable – and we now have the answer.”

EVERY’s technology enables year-round, geographically flexible production that is decoupled from livestock and feed markets and therefore completely devoid of avian flu risk, supply shocks, and salmonella outbreaks. EVERY’s proteins are also shelf-stable, with an 18-month shelf life and have a powder format, simplifying supply chain logistics and obviating the need for expensive cold chains – a major advantage for bakeries across the world who rely on refrigerated liquid eggs. The Company is consistently manufacturing metric tons of product every month at commercial scale and rapidly expanding its footprint which will enable it to reliably meet the demands of the world’s largest food brands.

“EVERY is proving what this technology can do — real products solving real customer problems, at industrial scale, with a clear path to profitability,” said Phil Morle, Partner at Main Sequence. “Their progress shows how biomanufacturing has matured into a resilient, scalable part of the global food supply chain. This is a massive opportunity to build the next generation of food production.”

About EVERY™:

EVERY™ is a San-Francisco-based food technology company on a mission to build a more secure and accessible global food system by supplying food and beverage companies with egg protein ingredients made using precision fermentation.

EVERY’s line of innovative, FDA-approved ingredients includes OvoPro™ (ovalbumin, formerly EVERY EggWhite) which replaces the functionality of egg and egg whites in a range of applications, and OvoBoost™ (formerly EVERY Protein), a highly soluble, taste and texture neutral protein that can be used to fortify a wide variety of food and beverage products including coffees, juices, sodas, syrups, and baked goods.

For more on EVERY's B2B solutions transforming the food industry, visit EVERY.com.

About McWin Capital Partners:

McWin Capital Partners (“McWin”) is a specialist private equity and venture capital firm, dedicated to the food ecosystem. With deep industry expertise across three business segments; Food Tech, Foodservice and Restaurants, McWin’s purpose is to lead the food industry through positive change and create value on behalf of investors and portfolio companies of the McWin Funds by leveraging its scale, network and experience to deliver outstanding returns. McWin employs more than 30 people across EMEA and the US.

McWin Capital Partners is the trading name for McWin Advisers UK Limited. McWin Advisers UK Limited is an appointed representative of G10 Capital Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 648953). For more information, visit https://mcwin.fund/.

Important Notice

The Fund mentioned within this communication is only available to Professional Investors and Retail Investors may not rely on the information within. This is not an offer to sell, or an invitation for an offer to acquire, an interest in the Fund, nor is it an invitation to apply to participate in the Fund. This is not an offering or placement of interests in the Fund in any jurisdiction and should not be construed as such. No information in this document will form the basis of any contract.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028242849/en/